Aquestive Therapeutics to Unveil Clinical Findings on Anaphylmв„ў at AAAAI Annual Meeting

Aquestive Therapeutics, based in Warren, New Jersey, is set to present new clinical data regarding its sublingual film, Anaphylm (dibutepinephrine), at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. This presentation, scheduled for February 2026, highlights significant advancements in the treatment of anaphylaxis, a severe allergic reaction that can be life-threatening.

The clinical data indicates that Anaphylm achieves effective epinephrine plasma concentrations without causing a dip in diastolic blood pressure, which is a common concern with traditional methods of epinephrine administration. This finding is particularly relevant as it may improve patient safety and comfort during critical allergic reactions.

The significance of this presentation lies in its potential to enhance the management of anaphylaxis, offering a new option for patients who require immediate treatment. As an innovative delivery method, Anaphylm could represent a shift in how allergic emergencies are addressed, underscoring Aquestive's commitment to advancing therapeutic solutions.